MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound GH501 and its use in treating bone metastatic castration-resistant prostate cancer.
MetCure Therapeutics LLC 